CN103211230A - Dietary fiber formulation and method of administration - Google Patents

Dietary fiber formulation and method of administration Download PDF

Info

Publication number
CN103211230A
CN103211230A CN2013101293999A CN201310129399A CN103211230A CN 103211230 A CN103211230 A CN 103211230A CN 2013101293999 A CN2013101293999 A CN 2013101293999A CN 201310129399 A CN201310129399 A CN 201310129399A CN 103211230 A CN103211230 A CN 103211230A
Authority
CN
China
Prior art keywords
fiber
fos
dietary fiber
formulation
soluble
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2013101293999A
Other languages
Chinese (zh)
Inventor
J·P·特鲁普
A·L·法尔克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nestec SA
Original Assignee
Nestec SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37835292&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN103211230(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nestec SA filed Critical Nestec SA
Publication of CN103211230A publication Critical patent/CN103211230A/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A23L29/20—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents
    • A23L29/206—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents of vegetable origin
    • A23L29/238—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents of vegetable origin from seeds, e.g. locust bean gum or guar gum
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A23L29/20—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents
    • A23L29/206—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents of vegetable origin
    • A23L29/244—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents of vegetable origin from corms, tubers or roots, e.g. glucomannan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Diabetes (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Dispersion Chemistry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The invention provides dietary fiber formulation and related methods for its administration. In one embodiment, the invention provides a dietary fiber formulation comprising: partially-hydrolyzed guar gum (PHGG); and fructooligosaccharides (FOS), wherein the dietary fiber formulation exhibits a prebiotic potential greater than a prebiotic potential of PHGG and FOS individually.

Description

Dietary fiber formulation and application process
The application submitted on October 23rd, 2006, denomination of invention is applied for dividing an application of PCT/US2006/041568 for the PCT of " dietary fiber formulation and application process ", it is on April 21st, 2008 that described PCT application enters the date in China national stage, and application number is 200680039184.6.
Technical field
The present invention relates generally to dietary fiber, more specifically, relates to the preparation and the application process thereof that comprise partial hydrolysis guar gum (PHGG) and FOS (FOS).
Background technology
Dietary fiber
Dietary fiber is a carbohydrate, the plant cell wall that this carbohydrate mainly digests from the opposing human chitinase.They are famous because of the ability that changes environment in the intestines, thereby along its physiology courses of whole length adjustment of intestines, the influence that it brought is had nothing in common with each other at small intestine and large intestine.The major function of fiber in small intestine is to improve viscosity, and it is used as the substrate of producing SCFA (SCFA) in large intestine.The fiber of different physical attributes and corresponding effect thereof promote the normal function of intestines jointly.
Fiber is carbohydrate and lignin, and described carbohydrate and lignin can not be produced hydrogen, methane, carbon dioxide, water and SCFA but can ferment by enterobacteria by the hydrolysis of people's digestive ferment institute.Fiber is classified based on its fermentability, dissolubility and viscosity usually.Most of fermentable fibers are soluble and viscosity, and most of insoluble fibre be non-sticky and do not have a complete fermentation.At present, nutrition is conceived to dissolubility and comes dietary fiber is classified.
Insoluble fibre comprises cellulose and lignin, is fully water-fast and slightly ferments in colon.They mainly play filler by the storage capacity of self.Insoluble fibre can increase the ight soil amount and promote normal processes through the content of enteron aisle, relief of constipation under the enough prerequisite of intake liquid.
Soluble Fiber is water-soluble and may be fermented by enteric bacteria, and 90% is grown in the colon in the described enterobacteria.Fermentability depends on the solubility and the granular size of fiber.For example, when a kind of dissolubility of fiber increases and its granular size when reducing, its can be fermented faster.Soluble Fiber gives the multiple beneficial effect in digestion process, as postponing gastric emptying to prolong period of satiety, slows down the speed of glucose absorption and the serum cholesterol that the marisone compound helps to reduce rising.Soluble Fiber comprises pectin, natural gum, some hemicellulose, fleabane, guar gum, FOS (FOS), inulin and galactooligosaccharide (GOS).In addition, a large amount of Soluble Fiber be present in fruit, vegetables and comprise barley and the cereal of oat in.
The extra beneficial effect of fiber and its fermentability and to produce SCFA relevant.Acetate, propionate and butyrate have comprised 83% of colon output SCFA.SCFA is easily enterocyte and absorbs, and the growth of transportation, water absorption and the intestines of energy and stimulation sodium is provided.By these mechanism, SCFA help normalization by prescription medicine, be exposed to the ight soil of pathogenetic bacteria and sick loose, the water sample that causes.In addition, as the preferred nutriment of mucous membrane of colon cell, butyrate plays a crucial role in the normal growth development that influences colon epithelial cell.Therefore, butyrate has active anticancer and helps the integrality of mucous membrane.These products help the health defendance oneself to avoid malignant progression and pathogenetic bacteria invasion separately.
On physiology, SCFA is present in the ileum with low concentration.The SCFA content of ileum may raise under some physiology and clinical condition.Numerous studies shows, SCFA appears at terminal ileum can be stimulated peristaltic contraction and increase tetanic activity, and this activity can cause that emptying replys.Therefore, fiber produces that a large amount of SCFA can increase intestinal motility and the constipation of may releiving.
The concentration of SCFA is the highest at nearside large intestine place, mainly is because the availability of carbohydrate is bigger herein.The fermenting experiment that carries out the external use fecal bacteria proves that individual polysaccharide is decomposed with different speed.This discovery is relevant with the catabolic process of intestinal bacterium, because on sizable degree, but concentration of substrate adjusting organism is competed fermentation substrate in which way, and controlling mechanism participates in fermentation reaction in which way.
Studies show that, be present in the quantity that fiber type in the diet both can influence output SCFA in the sweat, can influence its ratio again.As if the production of acetate mainly from the fructose-6-phosphate phosphoketolase branch road by colon bacteria d glycolysis and Bifidobacterium.Propionate is mainly from the carbon dioxide fixation of bacteroid, and butyrate is mainly from the acetyl-S coacetylase condensation of carboxylic Pseudomonas and Eubacterium.
According to research reports, the highest acetate production is from glucose fermentation, following closely be the FOS fermentation.This may be respectively the result of glycolysis and Bifidobacterium branch road.High propionate production is realized by cellulose and PHGG fermentation and the fermentation acquisition by psyllium husk (psyllium husk) and PHGG of high butyrate levels.After 24 hours batch culture, the guar gum of partial hydrolysis (PHGG) output the SCFA of maximum quantity.
Microbial growth
SCFA is by the sanatory intestinal environment of some modes, and described mode comprises the growth that stimulates beneficial bacteria, as Bifidobacterium and Bacillus acidi lactici, and the growth that suppresses the harmful bacteria strain.Beneficial bacteria promotes intestinal health by the growth that excites positive immune response and competition to surpass harmful bacteria.Is so important just because of these reasons SCFA after the activity that microorganism subgroup in the intestines is upset in extreme change and other known meeting of radiotherapy, antibiotic use, diet.The microorganism positive with its cultivation is associated, and Soluble Fiber has the effect of mild laxative, can help prevention or alleviate constipation.
People's enteron aisle can be counted as an ecosystem, wherein from the bacterial subpopulations of about 800 kinds of bacteriums with each other, the interaction between component of host intestinal epithelial cells and host immune system.When intestinal environment was fit to, specific bacterial subpopulations growth was vigorous.Nutrient availability, pH, physiology course and lack competitive bacterium, all mixed cell that can in intestines, settle down in a certain special time influence.
Bacteria beneficial is commonly referred to probio, has been used ratio and prevention or the treatment need medical condition to improve beneficial bacteria in the intestines for many years.The useful effectiveness that belongs to probio comprises and reduces the frequency follow the diarrhoea that antibiotic and chemotherapy occur and shorten its duration, excite positive immune response and reduce the enzyme that promotes cancer in the colon.For probio can promote the growth of beneficial bacteria in intestines, it must be under by survival in the process of stomach, and must keep it form the ability of cloning in distal small intestine and colon.Probio commonly used comprises the bacterial strain of Bacillus acidi lactici and Bifidobacterium.Common probio food source is the food of sour milk, buttermilk, kimchi, sauerkraut and other cultivations and fermentation.
Prebiotics is as the growth substrate that is present in the potential beneficial bacteria of colon.For instance, help to keep the growth and the function of mucous membrane, comprise that power and water separates the transhipment of matter by the beneficial bacteria of prebiotics support.Therefore, prebiotics is defined as indigestible COF, and its growth and/or activity by one of selectable stimulation or limited quantity bacterium is benefited the host, and described bacterium is can improve health status as everyone knows.Yet, according to this definition, the purposes of prebiotics to small part is expected to be, the expection host the microorganism defectiveness and useful prebiotics is provided.This definition means that also prebiotics plays the effect of the inner organism growth of independent stimulation large intestine.Yet bacterium also is present in terminal ileum, and prebiotics can stimulate these organic growths, also improves host's health.
Synbiotics (Synbiotics) is to make prebiotics that the host is benefited and the mixture of probio.This combination improve probio by upper stomach enteron aisle process viability and promote to settle down in that colon is more effective.Therefore, Synbiotics may have the net effect same with prebiotics, i.e. the growth of beneficial bacteria in colon.The patient who major abdominal surgery or after liver transplantation pipeline is irritated food gives and Synbiotics, shows that the POI incidence reduces, and these data are with parenteral alimentation or do not have the fiber duct feeding and relatively draw.
Immunological regulation and antiphlogistic effects
Inner link between gut flora, congenital immunity and the mucomembranous immune system, be considered to play key effect in healthy and Pathological Physiology that chronic destructive inflammation is potential, wherein said chronic destructive inflammation has showed the characteristics of IBD (IBD).Generally speaking, the enteron aisle colon bacteria will can not cause destructive inflammatory reaction in intestines.In fact, the product of known bacterial fermentation is all being brought into play positive and useful effect aspect epithelial cell and the colon homeostasis.SCFA is from the enteric bacteria fermentation of indigestible dietary carbohydrates, and it provides basic energy for colonic epithelium.The SCFA deficiency may cause a kind of generation of chronic intestinal inflammatory-colitis.
A research report, butyrate is replied gene and the protein expression that bacterium lipolysaccharide changes born of the same parents' inner cell adhesion molecule-1 (ICAM-1), IL-6, COX-2 and PGE2 in people's enteron aisle CMEC.This explanation butyrate plays the effect of immunological regulation and anti-angiogenic generation.
According to another report, butyrate can suppress vascular cell adhesion molecule-1 (VCAM-1) and the expression of ICAM-1 in Human umbilical vein endothelial cells (HUVEC) that TNF-α stimulates by the generation that reduces protein and specific mRNA via the activity that suppresses NF-kB.In addition, well-known butyrate can improve peroxisome Proliferator-activated receptor-α (PPAR-α).These results show, butyrate and may have antiinflammatory property not only in colon cell in endothelial cell.The anti-inflammatory of butyrate and antiatherogenic character may part owing to the activation of NF-kB and PPAR-α and the correlated expression of VCAM-1 and ICAM-1.
Butyrate transport
Recently, special g protein coupled receptor has been confirmed to be the acceptor of SCFA in the mammal, and it mainly is expressed on the cell membrane of immunocyte.The immunocyte that intestines are relevant is present in the lamina propria under epithelium layer just.Activate the required SCFA concentration of these acceptors approximately between 0.01mM and the about 1.0mM.Because the tube chamber concentration of SCFA is quite high in the colon,,, may reach such concentration at the SCFA of the serosa side of colonic epithelial cell layer by its absorption via the assistance of sodium-coupling monocarboxylate transporter albumen (SMCT).Therefore, these acceptors are with relevant with the multiple physiology and the pathological condition that relate to intestinal inflammatory and antineoplastic immune.The ability of the active absorption of transport protein mediation butyrate may be its basis at the colon function of tumor inhibition, and described butyrate is the inhibitor of histone deacetylase.
SCFA also can be used as the part of the specific g protein coupled receptor on the mutually U.S. immunocyte of intestines.Because the concentration of these saturated fatty acids is quite high in colon lumen, SMCT may promote the transcellular transport of these aliphatic acid from the tube chamber to the lamina propria, has immunocyte in lamina propria, thereby the contact between gut flora and the intestinal tract immune system is provided.
Several studies shows, uses the butyrate treatment to raise multiple transcription factor, such as the mRNA and the protein level of PPAR-γ and vitamin D receptor.Another studies show that butyrate influences the expression of PPAR-γ, but does not directly activate this receptor.PPAR-γ is a nuclear receptor, and it has controlled a large amount of expression of gene, and described gene relates to adipocyte differentiation, lipid-metabolism, insulin sensitivity, inflammation and atherosclerotic.Therefore, preferably, may play beneficial effect aspect treatment diabetes, angiocardiopathy and the intestinal inflammatory disease by the fiber of the microbial fermentation that produces butyrate.
Prebiotic potential
Dietary fiber is categorized as, and prebiotics can be regulated the growth of bacterial subpopulations, and then is defined as Synbiotics when it combines with exogenous bacteria beneficial or probio, and it can further support the health of digestive system.Soluble Fiber can have height, in or low prebiotic potential, depend on the ability that it stimulates beneficial bacteria growth, the length of its fermentation time and its are produced the quantity of SCFA.Insoluble fibre has only faint or does not have prebiotic effect because they can only minimally by intracolic bacterial fermentation.
The external quantitative methods of known use is measured the prebiotic effect of fiber.Fiber is measurement (MPE) to prebiotic effect for measurable usefulness of the growth of main bacteria species in people's enteron aisle (especially Bifidobacterium and Bacillus acidi lactici).MPE has three parts:
1. the speed of fiber fermentation;
2. the variation of bacterial community quantity; With
3.SCFA production.
Fiber fermentation speed is definite by the variation of fibre concentration in time course.Therefore, fibre concentration descends soon more, and then bacteria fermentation rate is fast more.The variation of bacterial community quantity is measured by " prebiotic index ", it thinks the positive-effect that increases to of Bifidobacterium, lactobacillus and eubacterial growth rate, and the increase of the growth rate of bacteroid, clostridium, Escherichia coli and sulfate reducing bacteria then is a negative effect.Different fibers is supported the growth of different bacteriums, thus the SCFA of output different types and/or quantity.Yet the usefulness of prebiotics is associated with the bacterium that produces lactic acid, Bifidobacterium and the basic production of lactic acid person's of conduct Bacillus acidi lactici usually.Therefore, lactic acid production provides qualitative and quantitative assessment to institute's detection fibers with respect to the ratio of SCFA total output.MPE provides the quantitative analysis of the prebiotic potential of fiber and more support to the special fiber benefit is provided.Therefore, MPE is used for determine promoting the kind of fiber of optimum digestive health and prevention or treatment enteron aisle phlegm disease and the useful tool of concrete quantity.
Beneficial bacteria and pathogenetic bacteria balance between the two is for safeguarding that normal intestinal physiology is very important, because this balance directly influences the digestion and the absorption of immunologic function and nutriment.Be chosen as digestive health the fiber of additional benefit is provided, described benefit comes from the ability that they influence the enteric bacteria subgroup.By this way, the indirect promotion of dietary fiber:
The improvement of mucosal barrier function prevents that pathogenetic bacteria from entering into blood flow from intestines;
Promote useful subgroup and reduce the pathogenetic bacteria subgroup;
Produce SCFA, the epithelial main energy source of large intestine; With
Improvement by the interaction partners host immune between intestines immunocyte and the pathogenetic bacteria.
The unique chemical of dietary fiber, biology and physical property are that it consumes wholesome reason.Fiber is fully absorbed in healthy suggestion to general crowd, because HFD can help to prevent and treat the various chronic diseases that influence digestive system and health other system.For example, dietary fiber has the effect of elevated blood pressure of making and cholesterol levels normalization, and relevant with the reduction cardiovascular disease risk.In addition, dietary fiber is a particular importance for the patient who looks after paediatrics and the old crowd of section and postoperative, critical illness and chronic disease.
For example, the patient of postoperative and critical illness, and those need the patient of the acute stage of EA, Soluble Fiber helps to prevent diarrhoea, often combines with the enteron aisle feeding.For the impaired patient of function of intestinal canal, it is appropriate using every liter 6 to 10g fiber.Clinical testing shows that the normal patient of postoperative patient and function of intestinal canal benefits from higher fiber intake, every liter 10 to 15g is an amount of replenishing.After major abdominal surgery or liver transfer operation, in its Enteral formulations, added among the patient of mixture of fiber and additional probio, the generation of POI has shown remarkable reduction, and in the patient who accepts conventional no fiber preparation, its result does not just have so satisfactory.
For suffering from chronic uncomfortable or disease and those need the patient of EA for a long time, take in insoluble simultaneously and Soluble Fiber is suitable.Constipation is common problem in these patients, often because the intake deficiency of motionless, advanced in age or fluid and/or fiber.Constipation is especially common in the patient of pipeline filling food.If can tolerate, the mixture of listing fiber in general crowd's recommendation ingesta in can help to prevent constipation and to the needs of the dependence of cathartic and enema.The prebiotic effect of Soluble Fiber, independent or with the probio combination, also can in the chronic disease patient, help to alleviate or prevent relevant with antibiotic or communicable diarrhoea.
Dietary recommendation
Diet lacks the danger that fiber can increase disease.By contrast, HFD can make digestive health normalization or improve.Comprise that the two the diet of fibre-enrich of solubility and insoluble fibre is encouraged.Suggestion picked-up health adult every day fiber is 20 to 35g.To the children at 2 years old and above age, every day, recommended intake added that by the age with children 5g converts.The fiber mean intake still is lower than recommended levels in the U.S., and typical intake on average has only every day 14 to 15g.The good source of dietary fiber comprises fruits and vegetables, full fiber and high fiber cereal products and beans.High these food of absorption generally are rare on the custom basis.In addition, popular numerous food product contains seldom dietary fiber in the western diet.Even edible individual of being rich in the diet of fiber may the fiber intake still be not enough to prevent constipation.Therefore, it is very important replenishing in this case.
Diet that fiber content is abundant and prevention and treatment disease association, wherein said disease comprises obesity, metabolic syndrome, heart disease, apoplexy, diabetes, colon cancer and digestive system disorder.Understand fiber and how to influence each other to promote the disease that health and/or treatment begin from commitment, wherein under the prerequisite that mechanism has been supposed, determined itself and the relevance in stage further with intestinal environment.
Fat
The enough dietary fibers of hint absorption on evidence can help to prevent body weight to increase and promotion loses weight.The action model of suggestion comprises slows down gastric emptying to prolong after the meal satiety and to cause the blood sugar regulation and control to improve high fibre diet after.Epidemiological study confirms that diet has the often thinner and unlikely adult's obesity than low fiber picked-up of the adult of higher fiber.In clinical testing, every day, additional 14g fiber caused reducing by 10% energy absorption and lose weight average 1.9 kilograms in 4 months time.
Heart disease and stroke
The viscous fiber that numerous clinical testing reports increases is taken in and has been reduced T-CHOL and low-density lipoprotein (LDL) cholesterol, the health care statement of food and drug administration's approved: " Soluble Fiber of food source such as oat bran; the part as low saturated fat and cholesterol diet can reduce the danger that suffers from a heart complaint ".In addition, the Macro or mass analysis of the perspective groups of 10 of fiber intake investigation is found, increased the 10g fiber every day and make the danger that is concerning coronary artery events descend 14% and descend 24% because of the death of coronary heart disease at US and European.The level that the meals of fibre-enrich also can help to bring high blood pressure down and raise.Get involved test for two and find, the intake that is increased fiber by oat grain and oat bran causes hypertensive appropriateness but significant the improvement.Though meals and the additional viscous fiber of taking in can effectively reduce the LDL cholesterol, large-scale epidemiological study provides strong evidence to show the risk that also can reduce coronary heart disease from full cereal, beans, these diet that are rich in fiber of fruits and vegetables.
Diabetes
Some perspective group investigation find that the diet that is rich in fiber is relevant with the risk that remarkable minimizing develops into diabetes B.No matter fiber edible is from food or replenishers, has been shown blood sugar and insulin replies and lipodogramme are had favorable influence.23 clinical test results find that HFD reduces between the level of postprandial blood sugar 13% to 21%, reduce between the LDL cholesterol levels 8% to 16%, reduce between the level 8% to 13% of triglyceride.On this basis, ADA approval provides glycosuria patient group useful dietary fiber, as is reflected in its recent proposals amount and is fiber every days 25 to 50g at least.
Metabolic syndrome
Metabolic syndrome is the disease that occurs among the adult.Medically be defined as the group of three or more following biological risk, described factor is: abdominal obesity, insulin resistance, dyslipidemia (high triglyceride and low hdl (HDL) cholesterol) and elevated blood pressure.Under the situation that metabolic syndrome exists, the risk of suffering from angiocardiopathy and diabetes increases severely.Recently epidemiological study confirms in eight years, all 20% of cardiovascular events and surpass 50% diabetes new case and betide the individuality of suffering from metabolic syndrome.Although the U.S. population above 20% has the risk of suffering from metabolic syndrome, this risk is relevant with some changeable lifestyle factors, comprises the intake of dietary fiber.For example, one more than 1500 age in 40 years old to 60 years old women's colony, the risk that metabolic syndrome takes place is significantly higher in the group of the dietary fiber of edible minimum intake, its intake approximately reaches half of advising intake every day for whenever eating the 2000 kilocalories of average 14.6g of absorption fibers.In general, usual diet pattern is confirmed to be and comprises more absorption fat, kilocalorie and sweet drink, and the vegetables of minimum intake and dietary fiber.Determining adventurous individuality, clinical application and behavior change targetedly, comprise that the nutrition with HFD gets involved, is vital to prevention of metabolic syndrome and potential complication thereof.
Colon cancer
Most of clinical testings that nineteen ninety carried out in the past find that the incidence of disease of colorectal cancer in the higher people of fiber intake reduces.Evidence suggests dietary fiber, particularly the fiber in solubility and fermentation source has the effect that prevents to bring out the toxin formation of cancer and quicken its drainage.In addition, the SCFA that fiber fermentation produces promotes colonic epithelial growth, makes tumour regression via positive immune response pathway, and is that the purpose regulatory gene is expressed with the anti-cancer phenotype.Yet great contact the between the risk of fiber intake and colorectal cancer do not found in nearest test.To one of these differences possible explanation, may be that present taxonomic hierarchies does not have difference between the fiber of full confirmation and relevant particular types of anti-cancer effect and quantity.Another kind of possibility is the effectiveness that some diet composition also may influence with fiber interaction and cancer is taken place.
Digestive disorders
Fiber plays a part crucial at general intestinal health.It has a comprehensive normalization effect to digestive system.The picked-up that increases fiber can prevent or relief of constipation that to satisfy recommendation this effect is by softening, increase volume and quickening content and realize by enteron aisle.Fiber can also prevent and treat diarrhoea, and this is for paediatrics, old section and critical illness and chronic disease patient particular importance.In addition, as indicated above, fiber is in prevention and treat in the digestive disorders of multiple and inflammation-related and play a crucial role.High fiber intake is relevant with the risk that reduces the trouble diverticulosis, and this disease is characterized as at colon and forms pouch.The risk that male sex who discovers high fiber intake suffers from diverticulitis can reduce by 42%.Return visit to IBS (IBS) patient recently shows that the interpolation of Soluble Fiber can significantly improve the symptom of IBS.Yet this improvement is not observed when the meal supplement insoluble fibre.In addition, impel patients of ulcerative colitis to take a turn for the better by the Synbiotics treatment.In a word, Soluble Fiber not only helps healthy individual helping to keep alimentary canal health, but also to cause because of uncomfortable or disease digestive function or go to bits individual useful.
Cholera
In cholera, it is influenced to reply the cholera toxin Small Intestine, and this influence relates to stimulate secretion process and reduce moisture and electrolytical absorption from the small intestine to the large intestine.The diarrhoea of the water sample of huge amount needs immediately, and not so fluid-supplement therapy can cause death.
The human colon has and absorbs moisture and electrolytical ability and can increase absorption when SCFA exists.SCFA also suppresses the chloride secretion of the c-AMP mediation in the colon.Partial hydrolysis guar gum (PHGG) is a water-soluble fibre (Benefiber), (ORS) discharges SCFA through fermentation in colon if add oral cavity ORS (ORS that WHO recommends does not contain other tangible fiber-contents things).The absorption of water and sodium in the SCFA stimulation colon, thus ight soil is discharged and the duration alleviating diarrhoea intensity of diarrhoea by reducing in cholera patient's treatment.
In open randomized controlled trial, 130 adult male cholera patients are studied; 65 examples are accepted a) ORS+25g Benefiber; B) 65 examples are only accepted ORS (control group).All patients accept fortimicin 300mg one time.
The result: baseline clinical characteristics is the tool comparativity between colony.Find that stool weight (g) does not have significant difference, mean+SD (Benefiber25g, 10206 ± 5770 relative comparison groups at the 1st in 24 hours, 10231 ± 3750), the 2nd 24 hours (Benefiber25g, 2418 ± 3472 relative comparison groups, 2172 ± 3931, p=0.708).The duration of the back diarrhoea of being admitted to hospital (hour) also similar in these two colonies (Benefiber25g, 31.4 ± 11.1 relative comparison groups, 32 ± 12.5).Yet, in fractional analysis (get rid of the very highly patient of diarrhoea, the 1st 24 hours stool weight is greater than 10 kilograms), in benefiber acceptance group, the 1st 24 hours stool weight obviously descend (Benefiber25g, 5940 ± 2920 relative comparisons 7913 ± 1515, p=0.001).Benefiber is added the stool weight that ORS that WHO recommends helps reducing the laxativeness patient.
II type cholera
The guar gum of partial hydrolysis is a water-soluble fibre, the entrance cavity ORS contains or replenish more than one at least water-soluble fibre if add, preferred 2 kinds or extra fiber source still less, more preferably a kind of extra fiber source, such as pectin, natural gum, some hemicelluloses, fleabane, other guar gum, FOS (FOS), inulin and galactooligosaccharide (GOS), preferred FOS or inulin, more preferably inulin, fiber will ferment at colon and discharge SCFA, ight soil is discharged and the duration alleviating diarrhoea intensity of diarrhoea by reducing in cholera patient's treatment, and effect is more a lot of by force with Benefiber than separately.
The guar gum of partial hydrolysis and FOS
The guar gum of partial hydrolysis (PHGG) (carrying this (Novartis) company as Nova sells with the Benefiber title) and this fiber of two types of FOS (FOS) are all by extensive studies.All proved separately and can promote digestive health.
PHGG is uniqueness, soluble, the functional fiber that extracts from the melon bean gum.The high viscosity of guar gum itself almost disappears after its hydrolysis, makes it to become the desirable additive of food liquid and nutritional preparation.
The useful effect of many PHGG is likely owing to this fact, because the butyrate that it almost completely ferments in colon and its produces is significantly more than other Soluble Fibers.Known butyrate is the preferred fuel of colon cell, and it works in cell proliferation, differentiation and the apoptosis of regulating small intestine.In PC fermentation rapidly, PHGG does not significantly increase the weight of ight soil as other Soluble Fibers.But many PHGG of studies show that especially help making intestines function normalization and prevent or alleviating diarrhoea and constipation in the responsive crowd of the patient who accepts EA and other enteron aisle allergy.
In a research, the age suffered from the children that acute watery diarrhea is less than 48 hours in 4 to 18 months, and ight soil is discharged and reduced and the shortening of diarrhoea duration after taking the oral cavity ORS that adds PHGG.In another research, adding PHGG in the preparation of chicken for the basis, to have strengthened the age be the recovery from illness that 5 to 24 months, watery diarrhea history continue to surpass 14 days children's diarrhae.
PHGG replenishes, and compares with the no fiber preparation of routine, has shown that can reduce pipeline irritates the incidence of disease that the gerontal patient of food suffers from diarrhoea.In a research, accept nobody experience intolerance among the PHGG patient of additional (20g every day), and four patients of the no fiber preparation of acceptance there is the filling of the necessary termination of continuation diarrhoea pipeline to eat.In another research, incremental supplementation PHGG in the standard Enteral formulations (from 7g every day, through increasing to 28g every day 4 weeks) can significantly reduce gerontal patient's times of defecation, increases the SCFA output, and makes enterobacteria balance normalization.Additional (every liter of the 22g) of PHGG also can reduce the diarrhoea situation of irritating the food patient in another group intestines.In addition, the diarrhoea outbreak of the patient's of the septic patient of recovery and force ventilation and intensive care unit continuation diarrhoea also can reduce fully.
PHGG can also effectively make constipation recover normal.In a research, the intrinsic constipation person of the long-term treatment by enema treatment, replenish (18g) that accept PHGG every day significantly reduced its demand to enema, the particularly initial higher intrinsic patient of enema consumption.In another research, PHGG replenish (15g every day) reduces using of constipation and cathartic in the intrinsic patient of the long-term treatment of the chronic cathartic of use.Compare with the object of accepting wheat bran (every day, the PHGG of 5g replenished); replenishing of PHGG also shows the interval (every day, the PHGG of 11g replenished) that can shorten its bowel movement in the women who suffers from constipation; make the adult intestinal movement normalization of suffering from IBS effectively, and improvement is suffered from abdominal pain and intestines are unusual.
PHGG is considered to prebiotics, because it has increased the concentration of beneficial bacteria strain Bifidobacterium and Bacillus acidi lactici.One studies show that, at the edible healthy philtrum that contains PHGG (21g every day) diet two weeks, Bifidobacterium increases by 17%.Also detect the Bacillus acidi lactici that growth increases simultaneously.The discovery of other reports is consistent with it, after the PHGG of daily additional absorption 8g every day, detects the Bacillus acidi lactici of remarkable increase.
FOS (FOS) is the short chain fructose polymer, often mentions in the same breath with long-chain fructose polymer inulin.Several plant is natural FOS source, comprises witloof, globe artichoke, asparagus and onion.Some productions or the known common practice of obtaining FOS comprise, for example,, hydrolysis of inulin synthetic from sucrose, extracts, extracts and extract from American aloe from the Jerusalem arithoke from the chickory root.As the fermentable fiber of the height of tool prebiotic activity, FOS is stimulating the growth of Bifidobacterium and Bacillus acidi lactici.As PHGG, studies show that FOS can prevent or symptoms such as alleviate constipation and diarrhoea.
By promoting the growth of Bifidobacterium, FOS promotes intestinal health, has strengthened the growth that positive immune response and inhibition may cause the pathogenic bacteria of suffering from diarrhoea.A research report shows, adds 4g FOS every day in the healthy adult human diet and can be increased in the just Bifidobacterium of next month.Some other research is also found in the diet in 14 days to replenish 4g FOS every day, and Bifidobacterium and Bacillus acidi lactici all have remarkable increasing degree.Existing in addition demonstration, give and 15g FOS every day, not only increased Bifidobacterium in 15 days that take in, and reduced the level of pathogen, particularly bacteroid, clostridium and fusiform bacilarmature.
By promoting the microbial balance of forward, FOS has strengthened the regularity of intestines.In the children's that accept antibiotic therapy multichannel test, the Synbiotics combination of Fos and Bacillus acidi lactici reduces the incidence of disease of diarrhoea.In the FOS+ lactobacilli supplementation group, 71% children experienced no tolerance problems, and 38% use the children of one group of placebo to experience diarrhoea.The duration of diarrhoea outbreak obviously shortens in the FOS+ lactobacilli supplementation group.In that group, diarrhoea has on average only continued 0.7 day, relative placebo average out to 1.6 days.Another studies show that, when the patient who suffers from constipation gives and FOS in the time of 28 days by a definite date, 73% patient's unusual symptom has and slows down.Equally, in the research to dialysis patient, for the similar formulations of no FOS, the kidney preparation that is supplemented with FOS can relief of constipation.
Although the above-mentioned dietary fiber that studies show that works aspect the host health keeping and improve, still needing dietary fiber formulation and application process thereof that it is used can provide wholesome benefit, and this benefit can not be provided or be provided greater than it by known formulations and method.Especially the dietary fiber formulation that needs prebiotic potential that can more abundant realization dietary fiber.
Summary of the invention
This invention provides dietary fiber formulation and relevant application process.In one embodiment, the dietary fiber formulation that provides of this invention comprises: the guar gum of partial hydrolysis (PHGG); And FOS (FOS), wherein the prebiotic potential that presents of dietary fiber formulation is greater than PHGG and the independent prebiotic potential of FOS.
This invention first aspect provides dietary fiber formulation, and it comprises: first Soluble Fiber; With second Soluble Fiber, wherein dietary fiber formulation presents prebiotic potential greater than first Soluble Fiber and the independent prebiotic potential of second Soluble Fiber.
This invention second aspect provides uses the individual method of dietary fiber formulation treatment, and this method comprises: use the dietary fiber formulation of effective dose to individuality, said preparation comprises: first Soluble Fiber; With second Soluble Fiber, wherein dietary fiber formulation presents prebiotic potential greater than first Soluble Fiber and the independent prebiotic potential of second Soluble Fiber.
The aspect of design illustration of the present invention is with the other problems of not discussing that solves the mentioned problem of this paper and may be found by those skilled in the art.
Detailed Description Of The Invention
As implied above, the invention provides dietary fiber formulation and related methods of administration thereof.Preparation of the present invention can be used and be used for, for example, treatment is individual, it suffers from the whichever in the situation that a series of diseases maybe need treat, comprising IBS (IBS), IBD (IBD), diarrhoea, constipation, diabetes, hypertension, dyslipidemia, obesity, heart disease and stroke.Equally, can use the growth that preparation of the present invention is used for promoting host's intestinal environment beneficial bacteria, thereby prevent or reduce the possibility that the host can suffer from this disease or medical condition.
As used herein, term " treatment " is meant the treatment and the healing property of prevention or preventing property or changes treatment of diseases, comprise that treatment has risk of catching or the doubtful patient who catches, and uncomfortable or be diagnosed as the patient who suffers from disease or medical condition.Therefore, " effective dose " is the individual disease of treatment or the amount of medical condition.
When surprisingly, the combination of having found FOS (FOS) and partial hydrolysis guar gum (PHGG) is than any independent using intestinal health there is bigger prebiotic effect.This true partly cause is, each fiber has different fermentation rates and active specific small intestine zone, the PHGG/FOS mixture has the fermentation time of prolongation at enteron aisle, and compare with independent arbitrary fiber, produce more kinds of dissimilar SCFAs (SCFA), particularly acetate, propionate and butyrate.According to PHGG of the present invention, FOS and PHGG/FOS mixture, its fermentation time, SCFA are produced and prebiotic potential more as shown in table 1.
The independent comparison with fiber benefit that mix of table 1
? PHGG FOS PHGG and FOS mixture
Fermentation time 1 0.5 1
SCFA produces 1.27 0.46 1
Prebiotic potential 0 0.67 1
Whole 2.27 1.63 3
Relative mark 76％ 54％ 100％
In general, these results show, compare with independent PHGG, and the bigger income of PHGG/FOS mixture tool 24% is compared the bigger income of mixture tool 46% with independent FOS.Be pointed out that the prebiotic potential of mixture is significantly higher than the prebiotic potential of independent PHGG or FOS.
Table 2 has shown with single fiber to be compared with fibre blend, and the more extensive income of PHGG/FOS mixture of the present invention is shown in measurement (MPE) value of the prebiotic effect of its calculating.Each value is in the presence of the human faecal mass bacterium, and the substrate of use 0.25%, 0.5% and 1.0% (w/v) ferments based on the batch culture that stirs, the pH value is controlled and gets.
The comparison of the MPE value of table 2 fiber and fibre blend
Figure BDA00003051108900151
Although table 2 is presented under 1% the substrate condition, FOS has bigger MPE value than FOS:PHGG mixture, is pointed out that independent FOS effectiveness in vivo, mainly occur in distal small intestine and PC, wherein its useful effect can not be made full use of by human body.On the contrary, in the body of FOS:PHGG mixture effect mainly occur in colon than distal part.
When the prebiotic potential of FOS and PHGG was carried out external assessment, the growth that the mixture of two kinds of fibers strengthens beneficial bacteria strain Bifidobacterium and Bacillus acidi lactici reached the degree more than or equal to arbitrary independent fiber.When utilizing crossing research design to assess prebiotic potential, use the FOS of 6.6g and 3.4g PHGG21 days every day after, compare with initial level or those levels that reached after placebo period at 21 days, Bifidobacterium significantly increases.After FOS and PHGG mixture replenish and were ended seven days, level before bifidobacteria levels is got back to and handled.Volunteer with minimum beneficial bacteria initial level has obtained maximum integral body to be increased.
Mixture according to FOS of the present invention and PHGG combines the prebiotic activity of FOS and the high butyrate productivity of PHGG.Table 3 has been summed up the particular feature that mixture is compared with other fibers.The combination of FOS and PHGG has improved the especially level of butyrate of SCFA, provide strong promotion intestinal health and beneficial bacteria growth prebiotic benefit and on longer enteron aisle length, increase fermentation activity.Therefore, the mixture of FOS and PHGG maximization or surpassed the individual effects of each fiber and provide best income for intestinal health and function.
The attribute of table 3 dietary fiber
Figure BDA00003051108900161
FOS/PHGG mixture of the present invention is particularly conducive to the suffer from IBD individuality of (IBD).The intestinal mucosa of IBD infringement enteron aisle (mainly being colon).Under the situation of using the FOS/PHGG mixture, the fermentation of Soluble Fiber increases in the colon, causes the increase of SCFA output.Butyrate is the SCFA that is mainly produced by the PHGG fermentation, and is recognized that butyrate is the preferred fuel of colon cell, and the energy that described colon cell need be extra is with recovery and keep the function of being destroyed by IBD.By making up with Soluble Fiber, there is better chance to allow fiber contact surface area bigger in the colon and prolongation fermentation time, allow more substantial butyrate arrive the distal part of colon, mainly be the tissue that target is destroyed by ulcerative colitis.By combination FOS and PHGG, it is solubility and preferred fiber by the different bacterium fermentation, and butyrate output and prebiotic effect all are increased.
FOS/PHGG mixture of the present invention helps suffering from the individuality of IBS (IBS) equally.The PHGG aids gut motility, relief of constipation and diarrhoea, this is the sign of this disease.FOS has given prebiotic effect, rebuilds the in a healthy and balanced way of enteric bacteria.This is very useful, because suffer from many individualities of IBS higher coliform advantage of bacteria is arranged, and it may cause the imbalance of any number relevant with disease.
And, in nutritional preparation, list the Soluble Fiber mixture in, can increase the production and the secretion of glucagon-like-peptide-2 (GLP-2).GLP-2 is the special hormones of intestines, and it increases propagation and the differentiation and the minimizing enterocyte apoptosis of enterocyte.In addition, the location of specified protein and rich in the GLP-2 increase enterocyte is to increase the nutrient transport of enteron aisle.Soluble Fiber, and PHGG are particularly produced butyrate by preferred fermentation, think that this SCFA acts on the L cell (to produce the cell of GLP-2) to increase production and the secretion of GLP-2.GLP-2 is the important hormone that reduces intestinal inflammatory.Therefore, such as the fiber of PHGG, production and/or the secretion of its preferred GLP-2 of increasing that has the ability have the anti-inflammatory effect to enteron aisle.
Therefore, the mixture of FOS according to the present invention and PHGG is effectively alleviated the relevant symptom of IBD and IBS, is accompanied by as previously described to these and other diseases and disorderly possible treating and/or preventing.
For explaining and purpose of description that the front has proposed many-sided explanation of the present invention.It is not to be intended to exhaustive or to limit this invention with definite disclosed form, and obvious, and many modifications and variations all are possible.Such modifications and variations will be apparent to those skilled in the art, and are intended to be included in by within the determined scope of the present invention of appended claim.

Claims (31)

1. dietary fiber formulation, it comprises:
First Soluble Fiber; With
Second Soluble Fiber,
Wherein the prebiotic potential that presents of dietary fiber formulation is greater than first Soluble Fiber and the independent prebiotic potential of second Soluble Fiber.
2. the dietary fiber formulation of claim 1, wherein first Soluble Fiber comprises that the guar gum (PHGG) of partial hydrolysis and second Soluble Fiber comprise FOS (FOS).
3. the dietary fiber formulation of claim 2, wherein FOS is from following at least a generation:, hydrolysis of inulin synthetic from sucrose, extract, extract and extract from American aloe from the Jerusalem arithoke from the chickory root.
4. the dietary fiber formulation of claim 2, the ratio that wherein contains PHGG and FOS approximately is 2:1.
5. the dietary fiber formulation of claim 1, wherein this prebiotic potential comprises the ability that increases the enteric bacteria of at least a bacterial species number, described bacterial species is selected from the group of following composition: Bifidobacterium, Bacillus acidi lactici and eubacteria.
6. the dietary fiber formulation of claim 1, wherein this prebiotic potential comprises the ability of the enteric bacteria number that is reduced by at least a kind of bacterial species, described bacterium is selected from the group of following composition: bacteroid, clostridium, Escherichia coli and sulfate reducing bacteria.
7. the dietary fiber formulation of claim 1, wherein this prebiotic potential comprises the ability that increases the enteron aisle fermentation time.
8. the dietary fiber formulation of claim 1, wherein this prebiotic potential comprises the ability that produces SCFA (SCFA) that increases.
9. the dietary fiber formulation of claim 9, wherein this SCFA comprises following at least a: acetate, propionate and butyrate.
10. the dietary fiber formulation of claim 1 also comprises probio.
11. the dietary fiber formulation of claim 10, wherein this probio is selected from the group of following composition: Bifidobacterium, Bacillus acidi lactici and eubacteria.
12. the dietary fiber formulation of claim 1, wherein this prebiotic potential comprises that at least a part azymic of first Soluble Fiber and second Soluble Fiber passes the ability that arrives the middle part colon.
13. the dietary fiber formulation of claim 12, wherein this prebiotic potential comprises that at least a part azymic of first Soluble Fiber and second Soluble Fiber passes the ability that arrives distal colon.
14. the dietary fiber formulation of claim 1 is if wherein this prebiotic potential comprises that surf zone that at least a and colon of first Soluble Fiber and second Soluble Fiber contacts is greater than the ability that digests first Soluble Fiber and second Soluble Fiber respectively.
15. with the individual method of dietary fiber formulation treatment, this method comprises:
Use the dietary fiber formulation of effective dose to individuality, described preparation comprises:
First Soluble Fiber; With
Second Soluble Fiber,
Wherein the prebiotic potential that presents of dietary fiber formulation is greater than the prebiotic potential of independent first Soluble Fiber and second Soluble Fiber.
16. the method for claim 15, wherein this effective dose is to be enough to treat the disease at least a in the individuality and the amount of medical condition.
17. the method for claim 16, wherein this individuality suffers from following at least a: cholera, IBS, inflammatory bowel disease, diarrhoea, constipation, diabetes, hypertension, dyslipidemia, obesity, heart disease and stroke.
18. the method for claim 16 wherein should be recovered by operation by individuality.
19. the method for claim 16, wherein this body and function antibiotic therapy.
20. the method for claim 15, wherein this individuality has at least a risk: IBS, inflammatory bowel disease, diarrhoea, constipation, diabetes, hypertension, dyslipidemia, obesity, heart disease and stroke.
21. use the dietary fiber formulation treatment to suffer from the method for cholera individuality, this method comprises: at least a soluble dietary fibre preparations from effective dose to individuality that use.
22. the method for claim 21, wherein this Soluble Fiber is selected from the group that pectin, natural gum, some hemicelluloses, fleabane, guar gum, FOS (FOS), inulin and galactooligosaccharide (GOS) are formed.
23. the method for claim 21, wherein this Soluble Fiber is selected from the group of being made up of guar gum, FOS (FOS) and inulin.
24. the method for claim 21, wherein guar gum is the guar gum of partial hydrolysis.
25. the method for claim 21, wherein at least a Soluble Fiber are two kinds of Soluble Fibers.
26. the method for claim 25, wherein Soluble Fiber is selected from the group that guar gum, FOS (FOS) and inulin are formed.
27. the method for claim 25, wherein guar gum is the guar gum of partial hydrolysis.
28. the method for claim 25, wherein Soluble Fiber is guar gum and inulin.
29. the method for claim 25, wherein Soluble Fiber is guar gum and FOS (FOS).
30. the method for claim 21 and 25, wherein effective dose is the amount that is enough to treat at least a disease and medical condition in the individuality.
31. the method for claim 21 or 25, wherein this individuality is to use antibiotic to treat.
CN2013101293999A 2005-10-24 2006-10-23 Dietary fiber formulation and method of administration Pending CN103211230A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US72976705P 2005-10-24 2005-10-24
US60/729,767 2005-10-24
US74212405P 2005-12-02 2005-12-02
US60/742,124 2005-12-02

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CNA2006800391846A Division CN101291597A (en) 2005-10-24 2006-10-23 Dietary fiber formulation and method of administration

Publications (1)

Publication Number Publication Date
CN103211230A true CN103211230A (en) 2013-07-24

Family

ID=37835292

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2013101293999A Pending CN103211230A (en) 2005-10-24 2006-10-23 Dietary fiber formulation and method of administration

Country Status (15)

Country Link
US (1) US8530447B2 (en)
EP (1) EP1940243B1 (en)
JP (2) JP5030960B2 (en)
CN (1) CN103211230A (en)
AT (1) ATE518430T1 (en)
AU (1) AU2006306241B9 (en)
BR (1) BRPI0617746A2 (en)
CA (1) CA2626398C (en)
DK (1) DK1940243T3 (en)
HK (1) HK1118672A1 (en)
IL (1) IL188846A0 (en)
MY (1) MY144556A (en)
PT (1) PT1940243E (en)
RU (1) RU2395218C2 (en)
WO (1) WO2007050656A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106793824A (en) * 2014-10-01 2017-05-31 Mjn 美国控股有限责任公司 Micropopulation and the alimentation composition of metabolic characteristics that offer for gastroenteric environment improves
CN113615841A (en) * 2021-07-27 2021-11-09 自然资源部第一海洋研究所 Application of soluble dietary fiber in kelp in preparation of medicine and functional food for improving constipation

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0617746A2 (en) * 2005-10-24 2011-08-02 Nestec Sa formulation for food fiber and its use
KR101820024B1 (en) 2008-10-17 2018-01-18 사노피-아벤티스 도이칠란트 게엠베하 Combination of an insulin and a GLP-1 agonist
MX336030B (en) * 2009-05-11 2016-01-07 Nestec Sa LACTOBACILLUS JOHNSONII La1 NCC533 (CNCM I-1225) AND IMMUNE DISORDERS.
EP3831402A1 (en) 2009-11-13 2021-06-09 Sanofi-Aventis Deutschland GmbH Pharmaceutical composition comprising a glp-1 agonist, an insulin and methionine
MX2012005184A (en) 2009-11-13 2012-06-08 Sanofi Aventis Deutschland Pharmaceutical composition comprising a glp-1 agonist and methionine.
SI2568827T1 (en) * 2010-05-14 2018-10-30 Omega Pharma Innovation & Development Nv Composition for reducing absorption of dietary fat
AU2011202239C1 (en) 2010-05-19 2017-03-16 Sanofi Long-acting formulations of insulins
EP2608678A1 (en) 2010-08-25 2013-07-03 Tate & Lyle Ingredients Americas LLC Synbiotic product
RU2546520C2 (en) 2010-08-30 2015-04-10 Санофи-Авентис Дойчланд Гмбх Application of ave0010 for production of medication for treatment of type 2 diabetes mellitus
EP2478779A1 (en) 2011-01-24 2012-07-25 Biotechnobel Composition for providing beneficial health effects
EP2517699A1 (en) 2011-04-29 2012-10-31 Biotechnobel SA Composition for prevention and treatment of arthritis
ITMI20110791A1 (en) 2011-05-09 2012-11-10 Probiotical Spa BACTERIA OF BACTERIA ABLE TO METABOLIZE THE OXALATES.
ITMI20110793A1 (en) 2011-05-09 2012-11-10 Probiotical Spa STRAINS OF PROBIOTIC BACTERIA AND SYNBIOTIC COMPOSITION CONTAINING THEMSELVES INTENDED FOR THE BABY FOOD.
ITMI20110792A1 (en) 2011-05-09 2012-11-10 Probiotical Spa STRAINS OF BACTERIA BELONGING TO THE BIFIDOBACTERIUM TYPE FOR USE IN THE TREATMENT OF HYPERCOLESTEROLEMIA.
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
GB201112091D0 (en) 2011-07-14 2011-08-31 Gt Biolog Ltd Bacterial strains isolated from pigs
SI2750699T1 (en) 2011-08-29 2015-11-30 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for use in glycemic control in diabetes type 2 patients
AR087744A1 (en) 2011-09-01 2014-04-16 Sanofi Aventis Deutschland PHARMACEUTICAL COMPOSITION FOR USE IN THE TREATMENT OF A NEURODEGENERATIVE DISEASE
ITRM20110475A1 (en) * 2011-09-09 2013-03-10 Probiotical Spa BACTERIA OF LACTIC AND / OR BIFIED BACTERIA BACTERIA, OPTIONALLY ADDED TO N-ACETYLCISTEIN AND / OR LYSOZYME MICROINCAPSULATE GASTROPROTETTO, HAVING INHIBITION ACTIVITIES / REDUCTION OF THE GROWTH OF DIFFERENT E.COLI BIOTYPES, INCLUDING E.COLI O157: H7 E
GB201117313D0 (en) 2011-10-07 2011-11-16 Gt Biolog Ltd Bacterium for use in medicine
AR089719A1 (en) * 2012-01-16 2014-09-10 Glaxosmithkline Ip No 2 Ltd COMPOSITIONS AND METHODS TO TREAT DIABETES AND / OR OBESITY
KR101432884B1 (en) * 2012-04-27 2014-08-21 재단법인 전남생물산업진흥원 Anti-inflammatory agent containing helianthus tuberosus aerial part extracts
CN106620189B (en) * 2012-06-06 2021-11-19 上海交通大学 Method for improving intestinal flora structure and application
UA116550C2 (en) * 2012-11-06 2018-04-10 Гонсалес-де Ла Торре Хав'єр Microencapsulated bacterial consortium for the degradation of gluten into sourdough and method for producing said sourdough
US20150296851A1 (en) * 2012-11-27 2015-10-22 Shanghai Jiao Tong University Compositions for Balancing Gut Microbiota and the Preparation and the Uses thereof
GB201312713D0 (en) 2013-03-22 2013-08-28 Weaver Connie M Uses of soluble corn fibre for increasing colonic bacteria populations and increasing mineral absorption
CN110354255B (en) 2013-04-03 2024-05-14 赛诺菲 Treatment of diabetes by long acting insulin formulations
GB201306536D0 (en) 2013-04-10 2013-05-22 Gt Biolog Ltd Polypeptide and immune modulation
ITMI20130793A1 (en) 2013-05-14 2014-11-15 Probiotical Spa COMPOSITION INCLUDING LACTIC BACTERIA FOR USE IN THE PREVENTIVE AND / OR CURATIVE TREATMENT OF THE RECURRENT CYCLES.
EP3154558A4 (en) * 2014-06-13 2018-02-28 Gratuk Technologies Pty Ltd. Dietary supplement
CA3228950A1 (en) 2014-07-09 2016-01-14 Dsm Nutritional Products, Llc Oligosaccharide compositions and methods for producing thereof
WO2016029113A1 (en) * 2014-08-22 2016-02-25 Abbott Laboratories Methods of increasing endogenous production of beta-hydroxy-beta-methylbutyrate
ES2949095T3 (en) 2014-12-12 2023-09-25 Sanofi Aventis Deutschland Insulin glargine/lixisenatide fixed ratio formulation
HUE037476T2 (en) 2014-12-23 2018-08-28 4D Pharma Res Ltd Pirin polypeptide and immune modulation
NO3065748T3 (en) 2014-12-23 2018-04-21
EA201791702A1 (en) 2015-01-26 2018-04-30 Калейдо Байосайенсиз, Инк. THERAPEUTIC TOOLS ON THE BASIS OF GLYCANS AND RELATED METHODS
TWI748945B (en) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 Treatment type 2 diabetes mellitus patients
TW201705975A (en) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 Treatment of type 2 diabetes mellitus patients
JP2016192913A (en) * 2015-03-31 2016-11-17 株式会社東洋新薬 Exhaust retarder of food from stomach
AU2016253010B2 (en) 2015-04-23 2021-06-10 Kaleido Biosciences, Inc. Glycan therapeutics and methods of treatment
SG10201912319SA (en) 2015-06-15 2020-02-27 4D Pharma Res Ltd Compositions comprising bacterial strains
MA41010B1 (en) 2015-06-15 2020-01-31 4D Pharma Res Ltd Compositions comprising bacterial strains
EP3307288B1 (en) 2015-06-15 2019-07-24 4D Pharma Research Limited Compositions comprising bacterial strains
EP3240554B1 (en) 2015-06-15 2019-07-31 4D Pharma Research Limited Blautia stercosis and wexlerae for use in treating inflammatory and autoimmune diseases
MA41060B1 (en) 2015-06-15 2019-11-29 4D Pharma Res Ltd Compositions comprising bacterial strains
BR112018010089A2 (en) 2015-11-20 2018-11-13 4D Pharma Res Ltd compositions comprising bacterial strains
GB201520497D0 (en) 2015-11-20 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201520638D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201520631D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
JP6551934B2 (en) * 2015-12-18 2019-07-31 森永乳業株式会社 Bifidobacterium and / or lactic acid bacteria growth promoter and / or suppressor
GB201612191D0 (en) 2016-07-13 2016-08-24 4D Pharma Plc Compositions comprising bacterial strains
MD3313423T2 (en) 2016-03-04 2019-10-31 4D Pharma Plc Compositions comprising bacterial Blautia strains for treating visceral hypersensitivity
TWI802545B (en) 2016-07-13 2023-05-21 英商４Ｄ製藥有限公司 Compositions comprising bacterial strains
GB201617519D0 (en) 2016-10-14 2016-11-30 Genetic Analysis As A companion diagnostic method for use in the treatment of irritable bowel syndrome with dietary interventions or faecal microbiota transplant
GB201621123D0 (en) 2016-12-12 2017-01-25 4D Pharma Plc Compositions comprising bacterial strains
FR3064483B1 (en) * 2017-03-31 2022-06-03 Inra PERINATAL ADMINISTRATION OF SHORT-CHAIN FRUCTOOLIGOSACCHARIDES TO PREVENT METABOLIC DISORDERS ASSOCIATED WITH AN UNBALANCED DIET IN ADULTS
JP7212945B2 (en) 2017-05-22 2023-01-26 フォーディー ファーマ リサーチ リミテッド Compositions containing bacterial strains
CN107198250B (en) * 2017-05-23 2019-03-12 北京瑞千景科技发展有限公司 Improve intestinal microecology Chronic disease prevention composition and balanced nutritious food and application
JP6978514B2 (en) 2017-05-24 2021-12-08 フォーディー ファーマ リサーチ リミテッド4D Pharma Research Limited Composition containing bacterial strain
AU2018285445B2 (en) 2017-06-14 2020-03-26 Cj Bioscience, Inc. Compositions comprising bacterial strains
CA3066557A1 (en) 2017-06-14 2018-12-20 4D Pharma Research Limited Compositions comprising bacterial strains
LT3638271T (en) 2017-06-14 2021-01-11 4D Pharma Research Limited Compositions comprising bacterial strains
JP7576375B2 (en) 2017-11-03 2024-10-31 カレイド・バイオサイエンシズ・インコーポレイテッド Glycan preparations and methods of use for hyperammonemia
MX2021008072A (en) * 2019-01-18 2021-08-16 Cp Kelco Us Inc Prebiotic composition and its use.
WO2021028743A1 (en) * 2019-08-14 2021-02-18 Jeyakodi Shankaranarayanan Nutritional compositions for management of irritable bowel disease/syndrome and improve gut health
CN110731432A (en) * 2019-11-18 2020-01-31 青岛锦慧盛源生物科技发展有限公司 seaweed prebiotics stomach-protecting beverage and preparation method thereof
US20230083525A1 (en) * 2019-11-27 2023-03-16 Societe Des Produits Nestle S.A. Novel composition for reducing stress disorders

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6203797B1 (en) * 1998-01-06 2001-03-20 Stephen C. Perry Dietary supplement and method for use as a probiotic, for alleviating the symptons associated with irritable bowel syndrome
EP1243273A1 (en) * 2001-03-22 2002-09-25 Societe Des Produits Nestle S.A. Composition comprising a prebiotic for decreasing infammatory process and abnormal activation of non-specific immune parameters
EP1386546A1 (en) * 2002-07-31 2004-02-04 Ca.Di.Group S.r.l. Association of prebiotics and colonic foods intended to help and keep the physiological health and the functional capacity of the intestine
WO2004089115A1 (en) * 2003-04-08 2004-10-21 Novartis Ag Synbiotic combination
CN1561757A (en) * 2004-04-06 2005-01-12 李清山 Composite food fiber powder
WO2005006891A1 (en) * 2003-07-15 2005-01-27 Forum Bioscience Holdings Limited Carbohydrate substitute
WO2005056023A1 (en) * 2003-12-12 2005-06-23 Nova Biotics As Prebiotic combination products

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6200950B1 (en) 1998-02-18 2001-03-13 Nestec S.A. Calorically dense nutritional composition
US6355609B1 (en) 1999-04-14 2002-03-12 Nestec S.A. Methods for stabilizing liquid nutritional products and products so stabilized
AU730929B2 (en) 1999-07-06 2001-03-22 Nestec S.A. Composition and method for prolonging the useful life of enteral feeding tubes
US6592863B2 (en) * 2000-08-22 2003-07-15 Nestec S.A. Nutritional composition
US20040087490A1 (en) 2002-09-20 2004-05-06 Troup John P. Nutritional compositions
AU2004280375B2 (en) * 2003-10-02 2008-05-15 Nestec S.A. Prebiotic effect analysis
JP2005247775A (en) * 2004-03-05 2005-09-15 Sankyo Seiyaku Kogyo Kk Nutrient composition for prevention and treatment
BRPI0617746A2 (en) * 2005-10-24 2011-08-02 Nestec Sa formulation for food fiber and its use

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6203797B1 (en) * 1998-01-06 2001-03-20 Stephen C. Perry Dietary supplement and method for use as a probiotic, for alleviating the symptons associated with irritable bowel syndrome
EP1243273A1 (en) * 2001-03-22 2002-09-25 Societe Des Produits Nestle S.A. Composition comprising a prebiotic for decreasing infammatory process and abnormal activation of non-specific immune parameters
US20040219157A1 (en) * 2001-03-22 2004-11-04 Florence Rochat Composition comprising a prebiotic for decreasing inflammatory process and abnormal actibation of non-specific immune parameters
EP1386546A1 (en) * 2002-07-31 2004-02-04 Ca.Di.Group S.r.l. Association of prebiotics and colonic foods intended to help and keep the physiological health and the functional capacity of the intestine
WO2004089115A1 (en) * 2003-04-08 2004-10-21 Novartis Ag Synbiotic combination
WO2005006891A1 (en) * 2003-07-15 2005-01-27 Forum Bioscience Holdings Limited Carbohydrate substitute
WO2005056023A1 (en) * 2003-12-12 2005-06-23 Nova Biotics As Prebiotic combination products
CN1561757A (en) * 2004-04-06 2005-01-12 李清山 Composite food fiber powder

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106793824A (en) * 2014-10-01 2017-05-31 Mjn 美国控股有限责任公司 Micropopulation and the alimentation composition of metabolic characteristics that offer for gastroenteric environment improves
CN113615841A (en) * 2021-07-27 2021-11-09 自然资源部第一海洋研究所 Application of soluble dietary fiber in kelp in preparation of medicine and functional food for improving constipation

Also Published As

Publication number Publication date
EP1940243A2 (en) 2008-07-09
AU2006306241A1 (en) 2007-05-03
ATE518430T1 (en) 2011-08-15
MY144556A (en) 2011-09-30
IL188846A0 (en) 2008-04-13
PT1940243E (en) 2011-10-17
WO2007050656A2 (en) 2007-05-03
AU2006306241B9 (en) 2012-03-08
CA2626398A1 (en) 2007-05-03
EP1940243B1 (en) 2011-08-03
CA2626398C (en) 2011-04-19
RU2395218C2 (en) 2010-07-27
US8530447B2 (en) 2013-09-10
WO2007050656A3 (en) 2007-07-12
JP5030960B2 (en) 2012-09-19
JP2009511506A (en) 2009-03-19
US20100168056A1 (en) 2010-07-01
RU2008116057A (en) 2009-10-27
BRPI0617746A2 (en) 2011-08-02
DK1940243T3 (en) 2011-11-14
HK1118672A1 (en) 2009-02-20
JP2012111771A (en) 2012-06-14
AU2006306241B2 (en) 2012-02-16

Similar Documents

Publication Publication Date Title
CN103211230A (en) Dietary fiber formulation and method of administration
Loman et al. Prebiotic and probiotic treatment of nonalcoholic fatty liver disease: a systematic review and meta-analysis
Topping Cereal complex carbohydrates and their contribution to human health
Schneeman Gastrointestinal physiology and functions
Chen et al. Propionate may mediate the hypocholesterolemic effects of certain soluble plant fibers in cholesterol-fed rats
Shah et al. Health benefits of konjac glucomannan with special focus on diabetes
Sivieri et al. Insights on β-glucan as a prebiotic coadjuvant in the treatment of diabetes mellitus: A review
CN101163488A (en) Composition anti-inflammatoire de l'intestin comprenant des maltodextrines branchees
Meier et al. Consensus recommendations on the effects and benefits of fibre in clinical practice.
CN101291597A (en) Dietary fiber formulation and method of administration
KR20050014854A (en) Use of pullulan as a slowly digested carbohydrate
Zhang et al. Recent advances in developing butyrogenic functional foods to promote gut health
BE1020284A3 (en) COMPOSITION TO OBTAIN POSITIVE HEALTH EFFECTS.
CN112931883A (en) Prebiotic composition and preparation method and application thereof
Johnson Dietary fiber
Dahiya et al. Inclusion of dietary-fibers in nutrition provides prebiotic substrates to probiotics for the synthesis of beneficial metabolites SCFA to sustain gut health minimizing risk of IBS, IBD, CRC
Joy et al. Dietary Fiber Intake and Benefit of Colorectal Cancer
Vinayak et al. Prebiotics for probiotics
Hasbay Dietary fiber and nutrition
WO2008146050A1 (en) Medicinal-preventive nutrient combination and foodstuffs on the basis thereof
Akhtar et al. Neutraceutical properties of resistant starch
Bird et al. Resistant starches, fermentation, and large bowel health
EP3761995A1 (en) Yeast beta glucans
Wahlqvist et al. Macronutrients: carbohydrates
Manish et al. Role of Dietary Fibers in Chronic Kidney Disease Patients

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20130724